---
title: "Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294814269.md"
description: "Securing a groundbreaking regulatory approval for the first PROTAC, VEPPANU, has been a major achievement. It marks a significant milestone in the field of heterobifunctional protein degraders. Following the approval, the successful out-licensing to Rigel Pharmaceuticals has been completed. This development showcases the potential of PROTACs in the pharmaceutical industry. This is indeed a momentous accomplishment in the progress of targeted protein degradation."
datetime: "2026-08-04T11:02:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294814269.md)
  - [en](https://longbridge.com/en/news/294814269.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294814269.md)
generator: "portal-rs"
---

# Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Securing a groundbreaking regulatory approval for the first PROTAC, VEPPANU, has been a major achievement. It marks a significant milestone in the field of heterobifunctional protein degraders. Following the approval, the successful out-licensing to Rigel Pharmaceuticals has been completed. This development showcases the potential of PROTACs in the pharmaceutical industry. This is indeed a momentous accomplishment in the progress of targeted protein degradation.

### Related Stocks

- [ARVN.US](https://longbridge.com/en/quote/ARVN.US.md)
- [RIGL.US](https://longbridge.com/en/quote/RIGL.US.md)

## Related News & Research

- [Connor Clark & Lunn Investment Management Ltd. Invests $1.39 Million in Arvinas, Inc. $ARVN](https://longbridge.com/en/news/297417473.md)
- [Algert Global LLC Grows Stock Position in Arvinas, Inc. $ARVN](https://longbridge.com/en/news/297393652.md)
- [Gyre Therapeutics unveils capital-efficient global development strategy](https://longbridge.com/en/news/297075877.md)
- [Gyre Therapeutics forecasts FY26 ETUARY revenue at $100.5 million-$111 million](https://longbridge.com/en/news/297050802.md)
- [The protein-shredding revolution: Why Arvinas gave away the keys to its historic FDA approval](https://longbridge.com/en/news/291659953.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**